0
Signin
countryflagUS

18889881171

AAPL 169.3 -0.6047% MSFT 395.125 1.4885% GOOG 165.555 0.5558% GOOGL 163.795 0.6235% AMZN 178.86 2.2057% NVDA 830.03 -3.9339% META 439.1 2.0759% TSLA 179.995 -1.7923% TSM 134.94 -1.7475% LLY 776.75 -0.5569% V 267.29 -0.4914% AVGO 1242.86 -4.4152% JPM 191.86 0.0626% UNH 484.11 0.0848% NVO 129.21 0.7014% WMT 58.82 -0.893% LVMUY 164.02 -0.0792% XOM 116.06 -1.8686% LVMHF 822.33 -0.4443% MA 442.07 -2.0235%

DexCom Inc

Healthcare US DXCM

125.86USD
-1.53(1.20%)

Last update at 2024-05-01T20:09:00Z

Day Range

123.52128.74
LowHigh

52 Week Range

74.75139.55
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 390.80M 173.90M 225.00M 104.20M -126.50000M
Minority interest - - - - -
Net income 341.20M 154.70M 493.60M 101.10M -127.10000M
Selling general administrative 1000.20M 810.50M 620.70M 515.70M 432.80M
Selling and marketing expenses - - - - -
Gross profit 1883.10M 1680.50M 1280.10M 931.50M 663.90M
Reconciled depreciation 155.90M 102.00M 67.10M 48.70M 29.10M
Ebit 391.20M 175.40M 299.50M 142.30M -132.90000M
Ebitda 416.90M 277.40M 382.70M 164.50M -103.80000M
Depreciation and amortization 25.70M 102.00M 83.20M 22.20M 29.10M
Non operating income net other 18.00M -3.20000M 10.20M 26.40M -
Operating income 391.20M 175.40M 299.50M 142.30M -186.30000M
Other operating expenses 2518.60M 2182.70M 1627.20M 1333.70M 1217.90M
Interest expense 18.60M 102.00M 84.70M 60.30M 22.70M
Tax provision 49.60M 19.20M -268.60000M 3.10M 0.60M
Interest income 18.00M - 16.10M 26.40M 2.40M
Net interest income -18.60000M -100.30000M -68.60000M -33.90000M -20.30000M
Extraordinary items - - - - 0.40M
Non recurring - - - - -
Other items - - - - -
Income tax expense 49.60M 19.20M -268.60000M 3.10M 0.60M
Total revenue 2909.80M 2448.50M 1926.70M 1476.00M 1031.60M
Total operating expenses 1491.90M 1414.70M 980.60M 789.20M 850.20M
Cost of revenue 1026.70M 768.00M 646.60M 544.50M 367.70M
Total other income expense net -0.40000M -1.50000M -74.50000M -38.10000M 80.10M
Discontinued operations - - - - -
Net income from continuing ops 341.20M 154.70M 493.60M 101.10M -127.10000M
Net income applicable to common shares 341.20M 154.70M 493.60M 101.10M -127.10000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 5391.70M 4863.60M 4290.50M 2395.00M 1916.00M
Intangible assets 173.30M 42.00M - - -
Earning assets - - - - -
Other current assets 192.60M 81.60M 53.90M 30.00M 16.50M
Total liab 3259.90M 2612.10M 2464.00M 1512.40M 1252.70M
Total stockholder equity 2131.80M 2251.50M 1826.50M 882.60M 663.30M
Deferred long term liab - - - - -
Other current liab 134.30M 125.20M 432.10M 88.50M 60.70M
Common stock 0.40M 0.10M 0.10M 0.10M 0.10M
Capital stock 0.40M 0.10M 0.10M 0.10M 0.10M
Retained earnings 479.90M -47.40000M -202.10000M -695.70000M -798.90000M
Other liab 68.70M 90.00M 80.90M 5.70M 12.70M
Good will 25.70M 26.50M 19.30M 18.60M 18.70M
Other assets 369.30M 220.80M 237.80M 14.20M 14.70M
Cash 642.30M 1052.60M 817.60M 446.20M 1137.00M
Cash and equivalents - - - - -
Total current liabilities 1839.30M 720.80M 614.10M 360.20M 222.40M
Current deferred revenue 10.10M 2.10M 2.20M 1.70M 2.90M
Net debt 1443.10M 769.20M 1021.90M 699.50M -126.70000M
Short term debt 793.10M 20.50M 16.50M 13.60M 11.70M
Short long term debt 772.60M - - - -
Short long term debt total 2085.40M 1821.80M 1839.50M 1145.70M 1010.30M
Other stockholder equity 1663.10M 2298.30M 2025.30M 1575.90M 1460.60M
Property plant equipment 1135.60M 889.90M 515.30M 321.30M 183.10M
Total current assets 3668.80M 3684.40M 3424.80M 1969.40M 1699.50M
Long term investments - - - - -
Net tangible assets 2131.80M 2183.00M 1826.50M 864.00M 644.60M
Short term investments 1813.90M 1678.60M 1890.10M 1087.10M 248.60M
Net receivables 713.30M 514.30M 428.50M 286.30M 226.70M
Long term debt 1197.70M 1702.70M 1667.20M 1059.70M 1010.30M
Inventory 306.70M 357.30M 234.70M 119.80M 70.70M
Accounts payable 901.80M 573.00M 163.30M 256.40M 147.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -11.60000M 0.50M 3.20M 2.30M 1.50M
Additional paid in capital - - - - -
Common stock total equity 0.40M 0.10M 0.10M 0.10M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity 479.90M -47.40000M -202.10000M -695.70000M -798.90000M
Treasury stock - -206.20000M -100.00000M -100.00000M -100.00000M
Accumulated amortization - - - - -
Non currrent assets other 47.10M 2.00M 21.40M 14.20M 14.70M
Deferred long term asset charges - - - - -
Non current assets total 1722.90M 1179.20M 865.70M 425.60M 216.50M
Capital lease obligations 174.70M 119.10M 172.30M 100.40M 7.30M
Long term debt total 1197.70M 1702.70M 1667.20M 1059.70M 1010.30M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -138.50000M 193.20M -807.70000M -835.20000M -61.40000M
Change to liabilities 303.60M 68.40M 220.60M 125.00M 80.00M
Total cashflows from investing activities -521.50000M -216.10000M -1018.00000M -1015.20000M -139.80000M
Net borrowings - - 1188.80M 906.20M 836.60M
Total cash from financing activities -552.50000M 10.40M 912.10M 10.70M 710.40M
Change to operating activities -128.90000M -11.00000M 22.90M 6.40M 20.80M
Net income 341.20M 154.70M 493.60M 101.10M -127.10000M
Change in cash -410.30000M 235.40M 371.80M -690.70000M 695.60M
Begin period cash flow 1053.60M 818.20M 446.40M 1137.10M 441.50M
End period cash flow 643.30M 1053.60M 818.20M 446.40M 1137.10M
Total cash from operating activities 669.50M 442.50M 475.60M 314.50M 123.20M
Issuance of capital stock 22.50M 20.30M 15.30M 11.90M 10.80M
Depreciation 155.90M 102.00M 67.10M 48.70M 29.10M
Other cashflows from investing activities -18.20000M -20.10000M -11.30000M -835.20000M -11.30000M
Dividends paid - - - - -
Change to inventory 49.30M -112.20000M -114.50000M -49.10000M -25.50000M
Change to account receivables -199.90000M -75.50000M -142.30000M -60.00000M -93.20000M
Sale purchase of stock -557.70000M 20.30M 15.30M 11.90M -100.00000M
Other cashflows from financing activities -17.30000M -9.90000M 1179.40M -1.20000M 799.60M
Change to netincome 145.90M 242.30M -64.30000M 109.00M 70.60M
Capital expenditures 364.80M 389.20M 199.00M 180.00M 67.10M
Change receivables -199.90000M -75.50000M -142.30000M -60.00000M -93.20000M
Cash flows other operating -126.50000M 62.80M 15.40M -9.80000M 171.40M
Exchange rate changes - - - - -
Cash and cash equivalents changes -404.50000M 236.80M 369.70M -690.00000M 693.80M
Change in working capital 27.70M -132.00000M -20.80000M 6.10M -40.90000M
Stock based compensation 126.50M 113.40M 119.40M 102.70M 101.90M
Other non cash items 39.80M 209.30M 93.60M 51.70M 240.30M
Free cash flow 304.70M 53.30M 276.60M 134.50M 56.10M

Fundamentals

  • Previous Close 127.39
  • Market Cap47056.58M
  • Volume2877573
  • P/E Ratio135.48
  • Dividend Yield0.41%
  • EBITDA659.60M
  • Revenue TTM3403.00M
  • Revenue Per Share TTM8.80
  • Gross Profit TTM 1883.10M
  • Diluted EPS TTM0.91

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DXCM
DexCom Inc		 -1.53 1.20% 125.86 135.48 71.43 13.83 20.76 13.68 59.13
ABT
Abbott Laboratories		 0.32 0.30% 106.29 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation		 -8.38 2.49% 328.12 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 0.65 0.81% 80.89 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.34 0.47% 72.21 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

View All

Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Inc

6340 Sequence Drive, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Mr. Kevin Ronald Sayer Exec. Chairman, CEO & Pres 1958
Mr. Jereme M. Sylvain Exec. VP, CFO & Chief Accounting Officer 1980
Mr. Jacob Steven Leach Exec. VP & COO 1978
Mr. Paul R. Flynn Exec. VP of Global Revenue 1969
Mr. Sean Christensen Director of Corp. Affairs & Head of Investor Relations NA
Mr. Michael Brown Exec. VP & Chief Legal Officer 1970
Mr. Matthew Dolan Exec. VP of Strategy, Corp. Devel. & Dexcom Labs 1981
Ms. Sadie M. Stern Exec. VP & Chief HR Officer 1975
Mr. Andrew K. Balo Exec. VP of Global Medical Affairs, Access & Evidence 1948
Mr. Steven R. Pacelli Exec. VP & MD of Dexcom Ventures 1972

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).